文献速递心力衰竭与心肌病

双向转诊模式对慢性心力衰竭患者治疗与预后的影响

[The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2025-01-01

本研究为双向队列研究,纳入357例慢性心力衰竭患者,比较双向转诊组(157例)与核心医院就诊组(200例)的随访率、药物使用率与达靶率及预后。结果显示双向转诊组12个月随访率更高,两组药物使用率无显著差异,核心医院组β受体阻滞剂和ACEI/ARB/ARNI达靶率较高但双向转诊并非负性预测因素,两组心功能指标改善趋势及心血管死亡和心衰再住院复合发生率无显著差异。

要点

  • 双向转诊组12个月随访率高于核心医院就诊组(73.8%比56.0%,P=0.004)。
  • 双向转诊模式并非β受体阻滞剂和ACEI/ARB/ARNI达靶率的负性影响因素(P均>0.05)。
  • 两组心血管死亡和心衰再住院复合发生率无显著差异(7.6%比6.5%,P=0.674)。

核心结论

  • 双向转诊模式在改善心衰患者依从性、药物使用率和达靶率方面具有一定优势,可促进心功能恢复并降低心血管死亡和心衰再住院风险,基本达到与核心医院就诊患者相当的治疗和管理效果。

研究设计与样本

  • 双向队列研究,纳入2018年3月至2022年3月于山东大学齐鲁医院或指定基层医院就诊的慢性心力衰竭患者357例,年龄53(41,63)岁,男性256例(71.7%)。
  • 双向转诊组157例(参与双向转诊模式且在基层医院至少随访1次),核心医院就诊组200例(仅于齐鲁医院就诊和随访)。

主要发现

  • 双向转诊组基线LVEF较低[28(22,34)%比31(23,36)%,P=0.021],收缩压较低[116(104,125)mmHg比121(109,134)mmHg,P=0.010]。
  • 双向转诊组12个月随访率较高(73.8%比56.0%,P=0.004)。
  • 随访期间两组β受体阻滞剂、ACEI/ARB/ARNI和钠-葡萄糖协同转运蛋白2抑制剂使用率差异无统计学意义(P均>0.05),醛固酮受体拮抗剂使用率均呈下降趋势。
  • 核心医院就诊组β受体阻滞剂达靶率(65.4%比49.3%,P=0.042)和ACEI/ARB/ARNI达靶率(79.8%比65.8%,P=0.046)较高,但多因素logistic回归显示双向转诊模式并非负性影响因素(P均>0.05)。
  • 两组NT-proBNP、LVEDd和LVEF均较基线改善(P均<0.001),变化趋势差异无统计学意义(P均>0.05);12个月心血管死亡和心衰再住院复合发生率(7.6%比6.5%,P=0.674)及累积发生率(log-rank P=0.684)差异无统计学意义。

临床怎么用

  • 对于慢性心衰患者,双向转诊模式可提高随访依从性,可作为核心医院与基层医院协同管理的可行策略。
  • 双向转诊模式不阻碍β受体阻滞剂和ACEI/ARB/ARNI的达靶,临床可放心在转诊体系中推进药物滴定。
  • 双向转诊模式下心功能指标和硬终点与核心医院就诊相当,支持在基层随访中管理稳定期心衰患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure. Methods: This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022. Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital). Baseline clinical characteristics were collected and compared between groups. Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate. Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization. Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels. Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses. Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients. Results: A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%). 157 patients were in the two-way referral group and 200 patients in the core hospital-treated group. Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, P=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), P=0.010). The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, P=0.004). No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all P>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups. Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, P=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, P=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all P>0.05). Both groups showed improved NT-proBNP, LVEDd, and LVEF from baseline (all P<0.001) with no significant difference in trends between groups (all P>0.05). There was no significant difference in the composite incidence (7.6% vs. 6.5%, P=0.674) and cumulative incidence (log-rank P=0.684) of cardiovascular death and heart failure rehospitalization at 12 months between two groups. Conclusion: The two-way referral model demonstrates advantages in improving medication adherence, drug utilization rates, and targetdoseachievement rates among CHF patients. This model not only promotes cardiac functional recovery but also reduces risks of cardiovascular mortality and heart failure rehospitalization, achieving comparable therapeutic and management outcomes to those observed in core hospital-treated patients. 目的: 探讨双向转诊模式对心力衰竭患者依从性和预后的影响。 方法: 本研究为双向队列研究。纳入2018年3月—2022年3月于山东大学齐鲁医院或指定基层医院就诊的慢性心力衰竭患者,根据是否转诊分为双向转诊组(参与双向转诊模式且在基层医院至少随访1次)和核心医院就诊组(仅于齐鲁医院就诊和随访),收集并比较2组患者的基线临床资料。对患者进行随访,主要终点为随访率、药物[β受体阻滞剂、血管紧张素转化酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)/血管紧张素受体脑啡肽酶抑制剂(ARNI)、钠-葡萄糖协同转运蛋白2抑制剂和醛固酮受体拮抗剂]使用率和达靶率,次要终点包括左心室射血分数(LVEF)、左心室舒张末期内径(LVEDd)和N末端B型利钠肽原(NT-proBNP)水平较基线的变化,以及心血管死亡和心力衰竭再住院。采用广义线性混合模型比较两组患者LVEF、LVEDd和NT-proBNP水平随时间的变化趋势。绘制Kaplan-Meier曲线和Cox回归曲线,比较两组患者的LVEF累积恢复率,并进行亚组分析。采用多因素logistic回归模型,分析影响慢性心力衰竭患者β受体阻滞剂和ACEI/ARB/ARNI达靶率的因素。 结果: 共纳入357例患者,年龄53(41,63)岁,男性256例(71.7%)。双向转诊组157例,核心医院就诊组200例。与核心医院就诊组相比,双向转诊组患者的基线LVEF[28(22,34)%比31(23,36)%,P=0.021]和收缩压[116(104,125)mmHg比121(109,134)mmHg(1 mmHg=0.133 kPa),P=0.010]较低,第12个月的随访率较高(73.8%比56.0%,P=0.004)。随访期间两组的β受体阻滞剂、ACEI/ARB/ARNI和钠-葡萄糖协同转运蛋白2抑制剂的使用率差异无统计学意义(P均>0.05),醛固酮受体拮抗剂的使用率均呈现随时间下降趋势。此外,尽管核心医院就诊组随访第12个月时β受体阻滞剂(65.4%比49.3%,P=0.042)和ACEI/ARB/ARNI(79.8%比65.8%,P=0.046)的达靶率较双向转诊组高,但多因素logistic回归分析显示,双向转诊模式并不是上述药物达靶率的负性影响因素(P均>0.05)。两组患者随访期间的NT-proBNP、LVEDd和LVEF水平均较基线改善(P均<0.001),且变化趋势差异无统计学意义(P均>0.05)。此外,两组患者随访12个月时的心血管死亡和心力衰竭再住院的复合发生率(7.6%比6.5%,P=0.674)及累积发生率(log-rank P=0.684)差异均无统计学意义。 结论: 双向转诊模式在改善心力衰竭患者的依从性、药物使用率和达靶率方面具有一定优势,该模式不仅促进患者心功能恢复,还能降低心血管死亡和心力衰竭再住院风险,基本达到与在核心医院就诊患者相当的治疗和管理效果。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Sun, Zhang, Hu, et al. [The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 41287294. doi:10.3760/cma.j.cn112148-20241216-00787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。